The Path to a Confirmed Diagnosis
At a Glance
APDS2 is confirmed by finding a disease-causing change in the PIK3R1 gene and interpreting it alongside antibody levels and immune-cell testing. Normal antibody levels or an atypical immune-cell pattern do not necessarily rule it out, so specialist review is important.
The diagnosis of APDS2 (also called PASLI-R1) is a multi-step process that moves from observing symptoms to finding the exact “on-switch” that is stuck in your immune system. Unlike some conditions diagnosed with a single blood test, APDS2 requires a combination of genetic data and specialized immune “mapping” called flow cytometry [1][2].
The Biological “On-Switch”
Inside your white blood cells, a pathway called PI3K delta acts like an engine that tells the cells when to grow and divide [3]. In a healthy immune system, a protein called p85α (made by the PIK3R1 gene) acts like a brake to keep this engine from running too fast [4].
In APDS2, a specific genetic error—most commonly one that causes a piece of the gene called exon 11 to be skipped (though other variants exist)—creates a shortened version of the p85α protein [4][5]. This “broken brake” allows the PI3K engine to run up to 300 times faster than normal [4]. This hyperactivity causes white blood cells to mature too quickly and “burn out” before they can properly fight infections [6].
Essential Diagnostic Tests
To confirm APDS2, doctors look for three main pieces of evidence. (It is important to know that normal immunoglobulin levels or non-classic flow cytometry results do not disprove a genetic diagnosis of APDS2, as these can be highly variable.)
- Serum Immunoglobulins: This measures the amount of protective antibodies in the blood. In 87% of patients, IgG and IgA (the primary infection-fighters) are low [1]. Interestingly, 58% of patients have high levels of IgM, which is an “early responder” antibody that isn’t as effective at long-term protection [1].
- Flow Cytometry: This test acts like a “census” for your immune cells. In APDS2, the “census” typically shows:
- Low Total B-cells: But a high percentage of transitional B-cells (immature cells that can’t finish growing up) [1][7].
- Low Naive T-cells: These are “rookie” cells that haven’t learned to fight specific germs yet [1].
- High Senescent T-cells: These are “exhausted” cells (often marked by CD57+) that have matured too fast and can no longer divide to fight new threats [6][8]. These subsets must be interpreted against age-matched reference ranges.
- Genetic Testing: This is the definitive “gold standard.” It must show a pathogenic variant (disease-causing error) in the PIK3R1 gene interpreted in clinical context [1].
Distinguishing APDS2 from Other Conditions
It is important to ensure your diagnosis is specifically APDS2, as it can be confused with other disorders:
- APDS1: Caused by a different gene (PIK3CD). While symptoms are similar, the genetic cause is different [9].
- Homozygous PIK3R1 Defects: This occurs when a person has two broken copies of the gene. Unlike the hyperactivity in APDS2, this causes a complete lack of B-cells and antibodies (agammaglobulinemia) [10].
- SHORT Syndrome: Some other variants in PIK3R1 cause SHORT syndrome, which features short stature and insulin issues but usually lacks the severe immune problems seen in APDS2 [11][12].
Completeness Checklist for Your Reports
When you receive your lab results, use this checklist to ensure the testing is complete. If items are missing, you can ask your immunologist to order the specific “subsets” or “panels” required.
| Test Category | What to Look For | Why It Matters |
|---|---|---|
| Genetic Report | PIK3R1 gene mentioned | Confirms the specific type of APDS. |
| Heterozygous zygosity | Means one copy is affected (standard for APDS2). | |
| Pathogenic Variant | Establishes the variant as disease-causing, such as a splice site variant (e.g., c.1425+1). | |
| Flow Cytometry | Transitional B-cells (CD24+ CD38+) | Shows if B-cells are getting “stuck” in development. |
| Naive T-cells (CD45RA+) | Shows if you have enough “rookie” cells to fight new germs. | |
| Senescent T-cells (CD57+) | Identifies “exhausted” cells that are burning out. | |
| Immune Panels | IgG, IgA, IgM levels | Essential for deciding if you need antibody replacement. |
| Vaccine response (Tetanus/Pneumo) | Shows if the immune system can actually “learn” from a vaccine (note: difficult to interpret if on replacement therapy). |
If your genetic test is unclear (a Variant of Uncertain Significance or VUS), it should not automatically be treated as disease-causing. You should consult a clinical geneticist for segregation analysis and expert clinical interpretation [2]. In selected cases to support expert evaluation, your doctor may order a phospho-flow test [2]. This specialized test directly measures if the AKT or S6 proteins are hyperactive inside your cells, providing functional proof [3][2].
Common questions in this guide
What tests confirm APDS2?
Can normal antibody levels or flow cytometry rule out APDS2?
What might flow cytometry show in APDS2?
What should I look for in a PIK3R1 genetic report?
What does a variant of uncertain significance mean for APDS2?
How is APDS2 different from APDS1 and other PIK3R1 conditions?
Why are vaccine antibody titers checked in APDS2?
Get notified when new evidence is published on immunodeficiency 132b.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E, Neven B, Bruneau J, et al.
The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.
PMID: 27221134 - 2
Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study.
Del Pino Molina L, Reche Yebra K, Soto Serrano Y, et al.
Frontiers in immunology 2024; (15()):1476218 doi:10.3389/fimmu.2024.1476218.
PMID: 39620215 - 3
Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T, Okada S, Tsumura M, et al.
Frontiers in immunology 2018; (9()):568 doi:10.3389/fimmu.2018.00568.
PMID: 29675019 - 4
Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.
Dornan GL, Siempelkamp BD, Jenkins ML, et al.
Proceedings of the National Academy of Sciences of the United States of America 2017; (114(8)):1982-1987 doi:10.1073/pnas.1617244114.
PMID: 28167755 - 5
Secondary C1q Deficiency in Activated PI3Kδ Syndrome Type 2.
Hong Y, Nanthapisal S, Omoyinmi E, et al.
Frontiers in immunology 2019; (10()):2589 doi:10.3389/fimmu.2019.02589.
PMID: 31781101 - 6
CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.
Cura Daball P, Ventura Ferreira MS, Ammann S, et al.
Immunology and cell biology 2018; (96(10)):1060-1071 doi:10.1111/imcb.12169.
PMID: 29790605 - 7
Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.
Wentink M, Dalm V, Lankester AC, et al.
Clinical immunology (Orlando, Fla.) 2017; (176()):77-86 doi:10.1016/j.clim.2017.01.004.
PMID: 28104464 - 8
[Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase δ syndrome 2].
Yang QY, Jia YJ, Wang YP, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; (58(5)):413-417 doi:10.3760/cma.j.cn112140-20190925-00614.
PMID: 32392959 - 9
Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T, Lau A, Bier J, et al.
The Journal of experimental medicine 2023; (220(6)) doi:10.1084/jem.20221020.
PMID: 36943234 - 10
A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects.
Bildik HN, Esenboga S, Halaclı SO, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2024; (35(9)):e14245 doi:10.1111/pai.14245.
PMID: 39312287 - 11
Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant.
Tomlinson PR, Knox R, Perisic O, et al.
bioRxiv : the preprint server for biology 2024; doi:10.1101/2023.11.02.565250.
PMID: 38077044 - 12
Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.
Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.
Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.
PMID: 35789397
This page explains APDS2 diagnostic testing for informational purposes only and does not constitute medical advice. Your immunologist and clinical geneticist can interpret your genetic, flow-cytometry, and immune-test results in context.